News wire article from our research archive:

Axcan Receives FDA Approval Letter for PYLERA'TM' -Formerly Known as HELIZIDE-, an Innovative 3-in-1 Capsule Triple Therapy for the Eradication of Helicobacter Pylori.

MONT-SAINT-HILAIRE, QUEBEC, Sep 29, 2006 (CCNMatthews via COMTEX) -- Axcan Pharma Inc. (TSX:AXP)(NASDAQ:AXCA) today announced that the US Food and Drug Administration ("FDA") has issued an approval letter for the Company's New Drug Application for PYLERA(TM) (formerly HELIZIDE). PYLERA(TM) is a patented 3-in-1 capsule triple therapy, for the eradication of Helicobacter pylori, which is a bacterium now recognized as being the main cause of gastric and duodenal ulcers. Each PYLERA(TM) capsule contains biskalcitrate potassium (140 mg), metronidazole (125 mg) and tetracycline hydrochloride (125 mg). The U.S. patent on the PYLERA(TM) capsule technology expires in December 2018.

...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!